Abstract
From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.
Original language | English |
---|---|
Pages (from-to) | 1105-1108 |
Number of pages | 4 |
Journal | Journal of Clinical Oncology |
Volume | 3 |
Issue number | 8 |
Publication status | Published - 1985 |
ASJC Scopus subject areas
- Cancer Research
- Oncology